Eurofins Achieved Revenues in Excess of EUR 5.4bn in 2020, After Continued Momentum in December Across Both Its Core Business and COVID-19 Related Activities - Seite 2
I would like to thank all our employees and leaders around the world for their remarkable commitment to our Testing for Life mission in 2020 which enabled Eurofins to significantly contribute to public health authorities’ fight against the pandemic and help ensure uninterrupted access to safe food, water and pharmaceuticals and other essential products and services to the public.”
For more information, please visit www.eurofins.com.
Notes to Editors:
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is a global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research Organisation services. Eurofins is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With over 50,000 staff across a decentralised and entrepreneurial network of more than 800 laboratories in over 50 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.
Lesen Sie auch
In 2020, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity for over 10 million patient tests per month to support efforts to identify and suppress the virus. The Group has established widespread PCR testing capabilities and has carried out over 10 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK testing, monitoring and consulting programmes to help ensure safer environments during COVID-19.